Investor FAQs

Tarsier® Pharma is a late clinical-stage biopharmaceutical company focused on developing bio-inspired therapeutic solutions for autoimmune and inflammatory ocular diseases. The company is publicly traded on the [Exchange] under the ticker [Ticker].

Tarsier® Pharma operates in the biopharmaceutical and life sciences sector, with a focus on ophthalmology and inflammatory ocular disease therapeutics.

Tarsier® Pharma trades on the [Exchange] under the ticker symbol [Ticker].

Tarsier® Pharma is headquartered in [City, State/Country].

Tarsier® Pharma was founded in [Year].

The Chief Executive Officer of Tarsier® Pharma is [CEO Name].

The executive leadership team includes: [CEO Name], Chief Executive Officer; [CFO Name], Chief Financial Officer; and other senior leadership.

Financial results, SEC filings, and earnings materials are available on the Investor Relations section of the Tarsier® Pharma website.

Tarsier® Pharma typically reports financial results quarterly. Upcoming earnings dates are listed on the Events & Presentations page of the Investor Relations website.

Live and archived earnings webcasts are available on the Events & Presentations section of the Investor Relations website.

Tarsier® Pharma is listed on the [Exchange].

The number of shares outstanding is reported in the company's latest SEC filings and quarterly earnings reports.

Tarsier® Pharma develops Dazdotuftide (TRS), a bio-inspired therapeutic platform designed to address autoimmune and inflammatory ocular diseases, including non-infectious anterior uveitis.

The company focuses on clinical advancement of Dazdotuftide through Phase 3 trials, market expansion into key ophthalmology markets, and building strategic partnerships to accelerate commercialization.

Investor inquiries can be directed to the Investor Relations team via the contact information provided on the Investor Relations section of the Tarsier® Pharma website.

SEC filings, including 10-K, 10-Q, and 8-K reports, are available in the SEC Filings section of the Investor Relations website.

Investor presentations and corporate materials are available on the Presentations page within the Investor Relations section.

Corporate governance materials, including board committee charters and governance guidelines, are available in the Governance section of the Investor Relations website.

The company's transfer agent is [Transfer Agent Name].

Shares of Tarsier® Pharma can be purchased through any brokerage firm that provides access to the exchange where the company is listed.